Reply

We appreciate the important questions raised by Vignesh et al regarding the use of tocilizumab in patients with MIS-C and the follow up of coronary abnormalities. Our study was a multi-institutional observational study without any intervention in medical management. Treatment and supportive therapies were based on institutional protocols and medical team clinical judgment. Various treatment modalities were used by different centers. Intravenous immunoglobulin (IVIG) was used in 54% of patients, corticosteroids in 51%, and IL-1 receptor antagonist (Anakinra) in 12%.
Source: The Journal of Pediatrics - Category: Pediatrics Authors: Tags: Letters to the Editor Source Type: research